Process leads to standardized psychedelic
extracts that are reproducible, scalable, cost-effective and
VANCOUVER, BC, June 24, 2021 /CNW/ - Numinus Wellness Inc.
("Numinus" or the "Company") (TSXV: NUMI), a mental health
care company advancing innovative treatments and safe,
evidence-based psychedelic-assisted therapies, is pleased to
announce that its subsidiary Numinus Bioscience Inc. ("Numinus
Bioscience") has filed a provisional patent application with the
United States Patent and Trademark Office (USPTO) for a process
that dramatically increases the production of therapeutics for use
in psychedelic-assisted psychotherapy.
The sustainable, reproducible and easily scalable process will
be used to rapidly generate therapeutic products from psychoactive
fungi species that contain psilocybin, other psychoactive compounds
and a range of additional beneficial compounds, some of which
Numinus researchers characterized for the first time in psychedelic
fungi. The resulting psychedelic products are intended to be
delivered in micro or macro dosages to help treat mental health
disorders that affect millions of people around the world.
"At Numinus, one of the key goals of our lab's research and
discovery work is to support accessibility to psychedelic-assisted
psychotherapies," said Sharan Sidhu,
Numinus Bioscience General Manager and Science Officer. "The rapid
production process announced today meets that goal by enhancing our
ability to seamlessly formulate safe and effective products with
consistent psychoactive properties at scale, with the regulatory
confidence that comes with standardized products."
Numinus initially tested the production process to rapidly
generate a Psilocybe species extract as 'proof of concept'.
Results revealed a highly efficient, scalable process that can be
applied to other species of psychoactive fungi. Numinus will assess
the clinical efficacy and safety of an extract generated using its
proprietary technology in an upcoming Phase 1 clinical trial, which
was announced in April 2021. The
Company's goal is to scale up the proprietary technology to make
psychedelic products generated from psychoactive fungi more readily
available in a market that may become regulated in the future.
"As research interest and demand for compassionate access to
psychedelics grows, patients will require safe therapeutic products
that offer consistent psychoactive properties and are scalable,"
said Payton Nyquvest, CEO, Numinus.
"With that in mind, we believe that the rapid production process
has the potential to transform the sector and ensure that as many
people as possible have the opportunity to benefit from mental
health treatments and support their wellbeing."
Today's announcement reinforces the leadership of the Numinus
Bioscience lab in novel psychedelic therapeutics development, and
highlights the opportunities resulting from the intellectual
property strategy that Numinus is pursuing. This includes basic
research into laboratory discoveries and processes that are
reproducible, sustainable, cost-efficient and patentable.
Under Canada's Controlled
Drugs and Substances Act, Numinus Bioscience can possess,
produce, assemble, sell, export, and deliver a wide variety of
psychedelics including Ketamine, Lysergic acid diethylamide (LSD),
Mescaline, N,N-Dimethyltryptamine (DMT), N-Methyl-3,4,
methylenedioxyamphetamine (MDMA), Psilocin and Psilocybin.
Numinus Wellness (TSX-V: NUMI) helps people to heal and be well
through the development and delivery of innovative mental health
care and access to safe, evidence-based psychedelic-assisted
therapies. The Numinus Wellness model - including psychedelic
production, research and clinic care - is at the forefront of
a transformation aimed at healing rather than managing symptoms for
depression, anxiety, trauma, pain and substance abuse. At Numinus,
we are leading the integration of psychedelic-assisted therapies
into mainstream clinical practice, and building the foundation for
a healthier society.
Learn more at numinus.ca, and follow us on Facebook, Twitter,
This news release contains forward-looking statements within
the meaning of applicable securities laws. All statements that are
not historical facts, including without limitation, statements
regarding future estimates, plans, programs, forecasts,
projections, objectives, assumptions, expectations or beliefs of
future performance, are "forward-looking statements".
Forward-looking statements can be identified by the use of words
such as "plans", "expects" or "does not expect", "is expected",
"estimates", "intends", "anticipates" or "does not anticipate", or
"believes", or variations of such words and phrases or statements
that certain actions, events or results "may", "could", "would",
"might" or "will" be taken, occur or be achieved. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause actual results,
events or developments to be materially different from any future
results, events or developments expressed or implied by such
forward-looking statements. Such risks and uncertainties include,
among others, dependence on obtaining and maintaining regulatory
approvals, including acquiring and renewing federal, provincial,
municipal, local or other licences and any inability to obtain all
necessary governmental approvals, licences and permits to operate
and expand the Company's facilities; regulatory or political change
such as changes in applicable laws and regulations, including
federal and provincial legalization of psychedelic therapies, due
to inconsistent public opinion, perception of the medical-use of
psychedelics, delays or inefficiencies or any other reasons; any
other factors or developments which may hinder market growth; the
Company's limited operating history and lack of historical profits;
reliance on management; the Company's requirements for additional
financing, and the effect of capital market conditions and other
factors on capital availability; competition, including from more
established or better financed competitors; the need to secure and
maintain corporate alliances and partnerships, including with
research and development institutions, customers and suppliers; the
development and implementation of medical protocols and treatment
standard operating procedures for the use of psychedelic therapies;
the Company's goals to develop and implement partnerships with
research organizations and other key players in the integrative
mental health industry; the Company's ability to successfully
withstand the economic impact of COVID-19; the medical benefits,
safety, efficacy, dosing and social acceptance of psychedelics; the
approval and/or success of compassionate access clinical trials;
the cultivation and harvest of Psilocybe mushrooms; and the
availability of trained personnel and medical professionals. These
factors should be considered carefully, and readers are cautioned
not to place undue reliance on such forward-looking statements.
Although the Company has attempted to identify important risk
factors that could cause actual actions, events or results to
differ materially from those described in forward-looking
statements, there may be other risk factors that cause actions,
events or results to differ from those anticipated, estimated or
intended. There can be no assurance that forward-looking statements
will prove to be accurate, as actual results and future events
could differ materially from those anticipated in forward-looking
statements. The Company has no obligation to update any
forward-looking statement, even if new information becomes
available as a result of future events, new information or for any
other reason except as required by law.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
View original content to download
SOURCE Numinus Wellness Inc.